Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
Eshal Amir, Student Member at American Academy of Neurology, shared a post on LinkedIn:
“Thrilled to share that two of my abstracts that were presented at American Heart Association Scientific Sessions, and has been published in Circulation (Impact Factor: 41.3)
Our first study looks at the cutting edge of thrombosis management, evaluating whether Factor XI inhibitors can optimize the balance between stroke prevention and bleeding risk in atrial fibrillation compared to current Factor Xa inhibitors.
Our second study takes a wider epidemiological lens, analyzing national mortality trajectories to identify high-risk demographic patterns in patients managing both hypertension and aortic aneurysm or dissection.
Grateful to my co-authors for their contributions and to the presenters for presenting it on the behalf of our team.”

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines
-
Nov 15, 2026, 20:50Asmaa Beltagy: Efficacy and Safety of Eltrombopag in SLE-Associated Immune Thrombocytopenia
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms